Agonist - Antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 192-200

  Edwards, W Barry ^a   Xu, Baogang ^a   Akers, Walter ^a   Cheney, Philip P ^a   Liang, Kexian ^a   Rogers, Buck E ^a   Anderson, Carolyn J ^a   Achilefu, Samuel ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; FLUORESCENCE; FLUORESCENCE MICROSCOPY; INFRARED DEVICES; MOLECULAR BIOLOGY; MOLECULAR IMAGING; PARTICLE BEAMS; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMORS;

BINDING AFFINITIES; BIODISTRIBUTIONS; IMAGING EVALUATION; IMAGING MODALITY; IN-VIVO; MONOMOLECULARS; MULTIMODAL IMAGING AGENTS; SOMATOSTATIN RECEPTORS; SYNTHESISED; TUMOUR TISSUE;

BINDING ENERGY;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; COPPER 64; CYPATE; FLUORESCENT DYE; LS 172; LUTETIUM 177; OCTREOTIDE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG LABELING; DRUG SYNTHESIS; ENDOCYTOSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

RATTUS;

EID: 38949118270     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700291m     Document Type: Article

References (34)

1. Gayed, I. W., Kim, E. E., Broussard, W. F., Evans, D., Lee, J., Broemeling, L. D., Ochoa, B. B., Moxley, D. M., Erwin, W. D., and Podoloff, D. A. (2005) The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J. Nucl. Med. 46, 248-252.
2. Jaffer, F. A., and Weissleder, R. (2005) Molecular imaging in the clinical arena. J. Am. Med. Assoc. 293, 855-862.
3. Zhang, Z., and Achilefu, S. (2005) Spectral properties of promultimodal imaging agents derived from a NIR dye and a metal chelator. Photochem. Photobiol. 81, 1499-1504.
4. Zhang, Z., Liang, K., Bloch, S., Berezin, M., and Achilefu, S. (2005) Monomolecular multimodal fluorescence-radioisotope imaging agents. Bioconjugate Chem. 16, 1232-1239.
5. Houston, J. P., Ke, S., Wang, W., Li, C., and Sevick-Muraca, E. M. (2005) Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J. Biomed. Opt. 10, 054010.
6. de Jong, M., Breeman, W. A., Bernard, B. F., Bakker, W. H., Schaar, M., van Gameren, A., Bugaj, J. E., Erion, J., Schmidt, M., Srinivasan, A., and Krenning, E. P. (2001) [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 92, 628-633.
7. Lewis, J. S., Wang, M., Laforest, R., Wang, F., Erion, J. L., Bugaj, J. E., Srinivasan, A., and Anderson, C. J. (2001) Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int. J. Cancer 94, 873-877.
8. Breeman, W. A., de Jong, M., de Blois, E., Bernard, B. F., Konijnenberg, M., and Krenning, E. P. (2005) Radiolabelling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging 32, 478-485.
9. Li, W. P., Lewis, J. S., Kim, J., Bugaj, J. E., Johnson, M. A., Erion, J. L., and Anderson, C. J. (2002) DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjugate Chem. 13, 721-728.
10. Storch, D., Behe, M., Walter, M. A., Chen, J., Powell, P., Mikolajczak, R., and Macke, H. R. (2005) Evaluation of [99mTc/ EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J. Nucl. Med. 46, 1561-1569.
11. Forrer, F., Waldherr, C., Maecke, H. R., and Mueller-Brand, J. (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 26, 703-707.
12. Hofland, L. J., and Lamberts, S. W. (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24, 28-47.
13. Bugaj, J. E., Achilefu, S., Dorshow, R. B., and Rajagopalan, R. (2001) Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J. Biomed. Opt. 6, 122-133.
14. Achilefu, S., Jimenez, H. N., Dorshow, R. B., Bugaj, J. E., Webb, E. G., Wilhelm, R. R., Rajagopalan, R., Johler, J., and Erion, J. L. (2002) Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J. Med. Chem. 45, 2003-2015.
15. Hofland, L. J., Lamberts, S. W., van Hagen, P. M., Reubi, J. C., Schaeffer, J., Waaijers, M., van Koetsveld, P. M., Srinivasan, A., Krenning, E. P., and Breeman, W. A. (2003) Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J. Nucl. Med. 44, 1315-1321.
16. Sprague, J. E., Peng, Y., Sun, X., Weisman, G. R., Wong, E. H., Achilefu, S., and Anderson, C. J. (2004) Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin. Cancer. Res. 10, 8674-8682.
17. Ye, Y., Li, W. P., Anderson, C. J., Kao, J., Nikiforovich, G. V., and Achilefu, S. (2003) Synthesis and characterization of a macrocyclic near-infrared optical scaffold. J. Am. Chem. Soc. 125, 7766-7767.
18. Parry, J. J., Eiblmaier, M., Andrews, R., Meyer, L. A., Higashikubo, R., Anderson, C. J., and Rogers, B. E. (2007) Characterization of somatostatin receptor subtype 2 expression in stably transfected a-427 human cancer cells. Mol. Imaging 6, 56-67.
19. Achilefu, S., Dorshow, R. B., Bugaj, J. E., and Rajagopalan, R. (2000) Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest. Radiol. 35, 479-485.
20. Breeman, W. A., De Jong, M., Visser, T. J., Erion, J. L., and Krenning, E. P. (2003) Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging 30, 917-920.
21. Rogers, B. E., Bigott, H. M., McCarthy, D. W., Della Manna, D., Kim, J., Sharp, T. L., and Welch, M. J. (2003) MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chem. 14, 756-763.
22. Edwards, W. B., Liang, K., Xu, B., Anderson, C. J., and Achilefu, S. (2006) Synthesis and radiolabeling of a somatostatin analog for multimodal imaging. Proc. SPIE 6097, 609701-609708.
23. Demas, J. N., and Crosby, G. A. (1971) Measurement of photoluminescence quantum yields. J. Phys. Chem. 75, 991-1023.
24. Philip, R., Penzkofer, A., Baumler, W., Szeimies, R. M., and Abels, C. (1996) Absortion and fluorescence spectroscopic investigation of indocyanine green. J. Photochem. Photobiol. A 96, 137-148.
25. Ye, Y., Bloch, S., Kao, J., and Achilefu, S. (2005) Multivalent carbocyanine molecular probes: synthesis and applications. Bioconjugate Chem. 16, 51-61.
26. Becker, A., Hessenius, C., Licha, K., Ebert, B., Sukowski, U., Semmler, W., Wiedenmann, B., and Grotzinger, C. (2001) Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. 19, 327-331.
27. Cescato, R., Schulz, S., Waser, B., Eltschinger, V., Rivier, J. E., Wester, H. J., Culler, M., Ginj, M., Liu, Q., Schonbrunn, A., and Reubi, J. C. (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 47, 502-511.
28. Reubi, J. C., Schar, J. C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., and Macke, H. R. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl Med. 27, 273-282.
29. Deshmukh, M. V., Voll, G., Kuhlewein, A., Macke, H., Schmitt, J., Kessler, H., and Gemmecker, G. (2005) NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide. J. Med. Chem. 48, 1506-1514.
30. Law, S. F., Yasuda, K., Bell, G. I., and Reisine, T. (1993) Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. J. Biol. Chem. 268, 10721-10727.
31. Liu, Q., Cescato, R., Dewi, D. A., Rivier, J., Reubi, J. C., and Schonbrunn, A. (2005) Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol. Pharmacol. 68, 90-101.
32. Beutler, D., Avoledo, P., Reubi, J. C., Macke, H. R., Muller-Brand, J., Merlo, A., and Kuhne, T. (2005) Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 103, 869-873.
33. Bodei, L., Paganelli, G., and Mariani, G. (2006) Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J. Nucl Med. 47, 375-377.
34. Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Macke, H. R., and Reubi, J. C. (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. U.S.A. 103, 16436-16441.